BASF ups Pronova bid


BASF has increased its offer for Norwegian firm Pronova BioPharma, which specialises in omega-3 fatty acids, from €664 million (£530 million) to €684 million in an attempt to win over reluctant shareholders.

The company made its initial offer in November 2012 with the support of the board and shareholders representing 60% of the company, including private equity fund Herkules, which owns a 50% stake.

Since then, the bid has been accepted by investors owning 70% of the issued shares. The new offer lasts until 18 January and will not be extended, BASF says.

Pronova makes active pharmaceutical ingredients based on omega-3 fatty acids that are used to treat cardiovascular conditions. It also makes dietary supplements. It employs 300 people and makes annual sales of about NOK1.7 billion (£180 million).

BASF strengthened its position in this growing market in May 2012 when it bought UK firm Equateq.


Related Content

BASF bids €664m for omega-3 company

22 November 2012 Business

news image

Pronova BioPharma makes pharmaceutical ingredients as well as nutritional supplements based in omega-3 fatty acids

BASF to cut 260 jobs in nutrition and health

1 May 2014 Business

news image

Firm to sell Norwegian site and shift focus towards Asia

Most Read

Photon pinball identifies chemicals from afar

13 August 2014 Research

news image

Samples turned into random Raman lasers beam their secrets from over a kilometre away

History of King Richard III written in his teeth

18 August 2014 Research

news image

Chemical analysis of isotope signatures in monarch's remains provide insight into his life

Most Commented

Catching criminals' coffee adulteration

12 August 2014 Research

news image

A test can detect unwelcome extra ingredients in coffee by analysing the drink's sugar fingerprint

Radiolabels help evaluate emerging cancer treatment

18 August 2014 Research

news image

Tracking tools will aid transition of boron neutron capture therapy from bench to hospital